Kornimate/medical-research-clean huggingface dataset:
registry for systemic eczema treatments

Conditions: Atopic Dermatitis

Summary: the registry for systemic eczema therapies (reset) registry is a database and biospecimen repository for patients with pediatric-onset atopic dermatitis (ad) who have used or will initiate any systemic treatment(s) for ad. the goal of the registry is to enable more efficient research recruitment and data collection as well as timely notification to enrollees about newly fda-approved treatments for ad.

the purpose of the registry for systemic eczema therapies (reset) registry is to serve as a database and biospecimen repository of patients with pediatric-onset atopic dermatitis (ad), also known as eczema. this registry seeks to enroll patients with ad who have used or will initiate any systemic treatment(s) for ad. such a registry will allow investigators to identify patients who are potentially eligible for ad research protocols, including observational studies or clinical trials. the registry will also prospectively collect data that would then serve as a resource for studying a variety of questions surrounding systemic therapy use in patients with ad, for example comparing the effectiveness of treatments or examining treatment effects on patient-reported outcomes. moreover, the registry would permit safety monitoring of systemic ad medications, as it would include both patients receiving traditional systemic agents with well-known side effect profiles and patients receiving more novel systemic agents with under-characterized side effect profiles. finally, this registry would allow for the identification of patients with moderate-to-severe ad who may be eligible to receive and benefit from the rapidly expanding number of u.s. food and drug administration (fda)-approved systemic therapies for ad.

Eligibility criteria:
inclusion criteria: * age \<26 years old * current physician diagnosis of atopic dermatitis * provide signed informed consent if ≥ 18 years old * provide signed informed consent by parent or legal guardian (if \<18 years old) and informed assent if applicable * subject and/or parent/legal guardian is willing to be contacted in the future by study staff * seen for clinical care at johns hopkins since 1/1/2017 * previously on, currently on, or planning to initiate (within next 6 months) a systemic ad therapy exclusion criteria: * age ≥26 years old at the time of registry enrollment * does not speak english * if \<18 years old, has a primary caretaker who does not speak english * if \<18 years old, parent/legal guardian is unwilling to sign the written informed consent * is a foster child * has not received clinical care at johns hopkins since 1/1/2017
bone microarchitecture in young cystic fibrosis patients

Conditions: Cystic Fibrosis

Summary: patients with cystic fibrosis are at risk of developing low bone mineral density (bmd) potentially leading to pathological fractures at adult age. recent data from our center and others have suggested that low bmd could be observed very early in life. however, quantitative bone abnormalities found out by dual x-ray absorptiometry (dxa) need to be confronted to qualitative evaluation of bone microarchitecture (surrogate of bone strength). high-resolution peripheral quantitative computed tomography (hr-pqct) is a recent technology with very high spatial resolution. images obtained with this technic are considered as virtual bone biopsies. it enables an accurate bones' cortical and trabecular surfaces exploration in a three-dimensional manner, and therefore provides informations on bone microarchitecture as well as bone density. the aim of this study is to evaluate bone microarchitecture of paediatric patients matched to sex-age-pubertal status-healthy volunteers. in the meantime, biological markers will be collected and dxa (dual-energy x-ray absorptiometry) will be performed in order to explore potential correlations hr-pqct parameters.


Eligibility criteria:
inclusion criteria: * cystic fibrosis patient of both sex * pubertal patient * age ≥10 years and ≤18 years on the date of informed consent * fev1(forced expiratory volume at one second ) ≥ 60% of predicted normal for age, gender and height * patient on a clinical stable period exclusion criteria: * unable to maintain arm and/or leg immobile for 3 minutes * history of solid organ transplantation * participation in the same time to a clinical trial * acute pulmonary exacerbation at the time of evaluation

Keywords: cystic fibrosis high-resolution peripheral quantitative computed tomography bone mass density
effects of regional anesthesia following mastectomy

Conditions: Postoperative Pain

Summary: patients of breast surgery dated between april 2016 and march 2021 will be scanned in three groups; solely induced general anesthesia, general anesthesia induced with erector spinae plane block, and general anesthesia induced with rhomboid block. the investigators aimed to retrospectively compare the effectiveness of regional anesthesia techniques used in the clinic for postoperative recovery and opioid consumption in patients who underwent breast surgery.


Eligibility criteria:
inclusion criteria: * patients underwent breast surgery under general anesthesia with or without one of the blocks; erector spinae plane block and rhomboid block. exclusion criteria: * incomplete patient forms.
a clinical study evaluating the safety and efficacy of si-614 ophthalmic solution in patients with dry eye.

Conditions: Dry Eye Syndromes

Summary: the purpose of this study is to assess the safety and effectiveness of si-614 solution compared with placebo solution in treating patients with dry eye.


Eligibility criteria:
inclusion criteria: * be at least 18 years of age * have provided written informed consent * have dry eye in both eyes exclusion criteria: * use of contact lenses * have an uncontrolled systemic disease * have an uncontrolled psychiatric condition, or substance or alcohol abuse * women who is pregnant, nursing or planning a pregnancy
patients' satisfaction after lasik

Conditions: Refractive Errors

Summary: the aim of this study is to evaluate the level of satisfaction, functional vision and quality of life outcome of patients after lasik surgery.

the feeling of sight in human is usually taken as the most significant factor for fathoming and receiving data from environment and, thus, assumes a significant role in regulating most human exercises and practices. accordingly, any harm to this sense may significantly influence an individual's adjustment with environment.1 refractive error can be explained as an eye condition in which incoming light rays are not focused on the photoreceptor layer of the fovea, resulting in blurred vision. of the refractive errors, myopia, hyperopia, and astigmatism are the 3 most common types. in myopia, the incoming light rays are focused in front of the fovea, whereas in hyperopia, they are focused beyond the fovea. astigmatism is typically explained by irregularities in the cornea (corneal astigmatism) and crystalline lens (lenticular astigmatism), which results in differential focusing of parallel rays through different corneal and lenticular meridians.the refractive surgery has a very important role helping subjects to get rid of contact lenses and spectacules.2-3 laser-assisted in situ keratomileusis (lasik) is the most popular refractive surgery performed to correct refractive errors of the eye, including myopia, hyperopia, and astigmatism. lasik surgery has been reported to yield significantly improved patient reported visual outcomes.1 the result is the patient's independence from glasses and contact lenses. many studies have reported that lasik surgery can improve not only visual function,1 but also patients' quality of life (qol).2,4-10 patient-reported outcomes also revealed that lasik can maximize patient satisfaction and quality of life by minimizing the onset of visual and dry eye symptoms.11 happiness or positive emotions are now regarded as a critical component of health.12 with the introduction of the discipline of positive psychology in the late 1990s, many scientific investigations of happiness have resulted in the development of the proposal that happiness or positive emotions are highly beneficial for physical and mental health.12-19

Eligibility criteria:
inclusion criteria: patients with myopia less than -10 diopters patients with hyperopia less than + 6 diopters exclusion criteria: patients of eye disease that may interfere with the results of the study. previous ocular surgery. patients using psychiatric medication will not be included in the study. unwillingness to participate in the study. subjects who did not respond to all questions were excluded.
pharmacokinetics of patupilone after a single intravenous administration in patients with advance solid tumor malignancies.

Conditions: Advanced Malignancies; Solid Tumors

Summary: the main purpose of this study is to characterize the distribution, metabolism, and elimination (adme) of patupilone after a single intravenous administration in patients with advanced solid tumor malignancies


Eligibility criteria:
inclusion criteria: 1. 18 years or older 2. world health organization (who) performance status score of: 0- you are fully active and more or less as you were before your illness, 1 - you cannot carry out heavy physical work, but can do anything else. 3. adequate hematological laboratory parameters 4. no major impairment of renal or hepatic function 5. female patients must have a negative serum pregnancy test at screening. exclusion criteria: 1. severe and/or uncontrolled medical disease; 2. severe cardiac insufficiency with uncontrolled and/or unstable cardiac or coronary artery disease; 3. known diagnosis of human immunodeficiency virus (hiv) infection; 4. presence of any other active or suspected acute or chronic uncontrolled infection; 5. symptomatic brain metastases or leptomeningeal disease. other protocol-defined inclusion/exclusion criteria may apply.

Keywords: epo patupilone solid tumors
gut hormones and roux en y gastric bypass

Conditions: Obesity; Type 2 Diabetes

Summary: the purpose of this study is to assess whether the changes in gut hormones seen following roux en y gastric bypass surgery are responsible for some of the beneficial effects seen post-operatively.

this study is designed to investigate whether chronic elevation of glucagon-like peptide-1 (glp-1), oxyntomodulin and peptide yy (pyy) in combination is responsible for the majority of the metabolic effects of roux-en-y gastric bypass (rygb) including improved glycaemia, increased energy expenditure, reduced food intake, weight loss, reduced preference for high calorie foods and reduced activation in brain reward areas in response to visual food cues.

Eligibility criteria:
inclusion criteria * aged 18 - 70 years. * male or female. * eligible for bariatric surgery under the nhs. * diagnosed with impaired glucose regulation or type 2 diabetes, according to who 2011 criteria. * those with diabetes should be stable and well controlled with either diet or one oral hypoglycaemic agent. * hba1c ≤9.0% or 74.9 mmol/mol. exclusion criteria * history of any medical, psychological or other condition, or use of any medications, including over-the-counter products, which, in the opinion of the investigators, would either interfere with the study or potentially cause harm to the volunteer. * without access at home to a telephone or other factor likely to interfere with ability to participate reliably in the study. * pregnancy or breastfeeding. * smokers. * unable to maintain adequate contraception for the duration of the study and for one month afterwards. * history of hypersensitivity to any of the components of the subcutaneous infusions. * donated blood during the preceding 3 months or intention to do so before the end of the study. * insulin treatment. * uncontrolled hypertension. * any other co-morbidity that would compromise the validity of the study or the safety of the participant such as heart failure, clinically apparent cardiovascular disease. * volunteers on anti-coagulants such as warfarin and factor xa inhibitors will not undergo adipose tissue biopsy. * unable to give informed consent. * previous bariatric surgery. * unable to undergo fmri due to: * claustrophobia. * pacemaker, metal implant, clips, implanted device, shrapnel or bullet, metal in eyes that precludes magnetic resonance imaging. * significant structural abnormality on magnetic resonance brain scan
pharmacokinetic evaluation of subcutaneous versus intravenous palonosetron in cancer treated with chemotherapy

Conditions: Emesis

Summary: this trial compares the pharmacokinetics of palonosetron administered subcutaneously and intravenously.

5-hydroxitryptamine3 antagonists are one of the mainstays of antiemetic treatment and they are administered either intravenously or orally. nevertheless sometimes neither administration route is feasible, such as in patients unable to admit oral intake managed in an outpatient setting. our objective is to evaluate the bioavailability of subcutaneous palonosetron.patients receiving platinum-based chemotherapy will be randomized to receive palonosetron 3 mg either subcutaneously or intravenously in a crossover manner during two cycles. blood and urine samples will be collected after each cycle. pharmacokinetics of subcutaneous and iv palonosetron will be prospectively compared.

Eligibility criteria:
inclusion criteria: * cancer patients receiving platinum-based chemotherapy adequate bone marrow, hepatic and renal function exclusion criteria: * pregnancy * serious concomitant diseases, in the invesgator´s criteria

Keywords: chemotherapy emesis palonosetron
dose escalation study of intravitreal 4d-110 in patients with choroideremia

Conditions: Choroideremia

Summary: this study will evaluate safety, tolerability, and preliminary efficacy of a single intravitreal (ivt) injection of a recombinant adeno-associated virus (aav) gene therapy, 4d-110, in male patients with genetically-confirmed choroideremia (chm).

this is an open-label, phase 1 study to evaluate safety and tolerability as well as preliminary efficacy of a single ivt injection of 4d-110 at three dose levels in male patients with genetically-confirmed chm.

Eligibility criteria:
key inclusion criteria: * diagnosis of chm defined as a pathogenic mutation in the chm gene, confirmed by genetic testing * both eyes must have ≥ 34 etdrs letters (\~20/200) key exclusion criteria: * clinically significant, active ocular or peri-ocular infection or inflammation in the study eye * patient has previously received any aav treatment * ocular conditions or ocular media opacity in either eye that would preclude the planned treatment (i.e. ivt injection) or interfere with the interpretation of study endpoints (e.g. significant lens opacity)

Keywords: chm transgene gene therapy aav
long-term monitoring of patients with cardiac amyloidosis with implantable event monitors

Conditions: TTR Cardiac Amyloidosis

Summary: researchers are gathering information to see if using an fda approved implantable device can help with monitoring of your heart arrhythmias.


Eligibility criteria:
inclusion criteria: * cardiac biopsy or technetium pyrophosphate scintigraphy confirmed patients * stage i, ii, and early and late stage iii in numbers as described , irrespective of ef or nyha functional class * patients aged 18 -85, both genders and of all races and ethnicities. * patients must be competent to give informed consent. * patients must be able to have the biomonitor 3 implanted. * amyloid stage i-iii patients with existing implantable cardiac devices such as pacemakers or defibrillators exclusion criteria: * significant coronary artery disease \> 75% luminal stenosis in at least 1 epicardial vessel (by cardiac catheterization or coronary computed tomography), or history of myocardial infarction or coronary revascularization. * congenital heart disease. * pregnant patients * patients whose heart failure is felt to be secondary to primary valvular disease (\>moderate/severe mitral regurgitation), uncorrected thyroid disease, obstructive or hypertrophic cardiomyopathy, pericardial disease or a systemic illness. * absolute contraindications to cardiac mri (such as renal failure with gfr\<30%). * unwilling or unable to provide informed consent. * patients with other life threatening diseases that would likely decrease their life expectancy over the next four years. * patients who are post cardiac transplant. * difficulty to attend the follow-up schedule due to a history of medical noncompliance, difficulty, or unwillingness to return to the study center for follow up. * evidence of ongoing bacteremia or sepsis preventing implantation of a device * unwilling or able to have the biomonitor 3 interrogated
bobath approach on hemiplegic shoulder pain

Conditions: Hemiplegic Shoulder Pain

Summary: in this study, it is investigated that whether bobath approach is superior to conventional physiotherapy in terms of improving hemiplegic shoulder pain, spasticity and upper extremity functionality in stroke patients.

objective: this study aims to determine the effect of bobath approach on hemiplegic shoulder pain, spasticity and upper extremity functionality in stroke patients. patients and methods: for this prospective, randomized, controlled and single-blind trial, 30 stroke patients aged 40-65 years with hemiplegic shoulder pain were included. patients were divided into two groups and randomized into these groups. only conventional physiotherapy was applied to the control group, whereas both conventional physiotherapy and bobath exercises were also applied to the experimental group. visual analog scale (horizontal) for shoulder pain, modified ashworth scale for spasticity and fugl-meyer assessment of the upper extremity for functionality were used for both pre-test and post-test.

Eligibility criteria:
inclusion criteria: * patients between the ages of 40 and 65 * patients who had a stroke for the first time and had a disease duration of at least four weeks * patients who were diagnosed with ischemic or hemorrhagic stroke * patients who had brunnstrom stage 3, 4 or 5 and had hemiplegic shoulder pain were included in the study. exclusion criteria: * patients with severe cognitive impairment who could not understand simple verbal commands * those who had severe dysarthria to prevent verbal communication * those with unilateral neglect syndrome * those with loss of sensation in the upper extremity of the hemiplegic side * those with botulinum toxin-a injected to the hemiplegic upper extremity muscles * those with previous shoulder-related trauma or pain history * those with other accompanying neurological disease were excluded from the study.

Keywords: hemiplegia hemiplegic shoulder pain neurodevelopmental treatment spasticity stroke
effectiveness of pulmonary rehabilitation program in patients with sars-cov-2 pneumonia

Conditions: Covid19; Covid19 Pneumonia; SARS-CoV 2 Pneumonia

Summary: the aim of the study is to investigate the efficacy of pulmonary rehabilitation (pr) program to patients with sars-cov-2 pneumonia in the post-acute period on pulmonary functions, exercise capacity and anxiety level. 100 patients diagnosed with sars-cov-2 pneumonia will be enrolled in this prospective, interventional study according to inclusion/exclusion criteria. patients will be evaluated and a personalized pr program will be organized before hospital discharge. after discharge, the pulmonary rehabilitation program will continue in telerehabilitation. in the telerehabilitation program, exercises will be supervised by a physiotherapist two days a week, and patients will be asked to do the exercises themselves for the other 3 days. patients will also receive exercise videos for these 3 days. patients will be followed for 4 weeks and will be called for final evaluation


Eligibility criteria:
inclusion criteria: * pneumonia without having severe findings or a need for oxygen support therapy (mild pneumonia) accompanying special conditions (chronic lung / heart disease / diabetes / hypertension / neuromuscular disease history / elderly / immobility etc.) * severe pneumonia (a suspicion of fever or respiratory tract infection and having one accompanying finding: respiration rate \>30/min; severe respiratory distress; or spo2 ≤93% in ambient air.) cases after they get clinically stable (decreased fever, reduced dyspnea, respiratory rate 90%) * at least 7 days since the diagnosis of sars-cov-2 in order to reduce the viral load and the risk of transmission * being able to make video calls for telerehabilitation exclusion criteria: * serious cardiovascular, cerebrovascular, neuromuscular and other systemic diseases that affect physical activity * psychiatric illness and cognitive deficit that will affect patient's exercise cooperation * pregnancy * the deterioration in the general condition of the patient, worsening of the lung findings * acute respiratory distress syndrome
a new strategy for preoperative drainage of resectable pancreatic head cancer combined severe obstructive jaundice

Conditions: Pancreatic Cancer; Obstructive Jaundice

Summary: severe obstructive jaundice caused by pancreatic head cancer usually requires preoperative biliary drainage, but its necessity and effectiveness are controversial, and specific strategies lack clear standards. this study proposed a new strategy for preoperative biliary drainage using serum prealbumin as the main evaluation index, and compared it with the traditional strategy using serum total bilirubin as the main evaluation index. through a randomized, controlled, multicenter prospective study, we explored the effects of different drainage strategies on the incidence of in-hospital complications and long-term prognosis of patients with resectable pancreatic head cancer, guided clinical decisions on preoperative drainage time and surgical timing, and provided high-quality evidence-based medicine for preoperative biliary drainage of pancreatic head cancer.


Eligibility criteria:
inclusion criteria: 1. pathological diagnosis of pancreatic head cancer, or clinical diagnosis of pancreatic head cancer after multidisciplinary discussion, clear presence of obstructive jaundice caused by pancreatic head tumor, and planned to undergo radical pancreaticoduodenectomy 2. preoperative imaging stage is resectable 3. baseline serum total bilirubin ≥ 250μmol/l, and no history of preoperative biliary drainage 4. age \>18 and ≤75 years old 5. ecog(eastern cooperative oncology group) physical score ≤ 2 6. signed informed consent, received preoperative endoscopic biliary drainage (ercp) and radical surgery timing evaluation exclusion criteria: 1. combined with other malignant tumors 2. combined with uncontrolled medical diseases or organ dysfunction and other absolute counterindications for surgery 3. pregnant and lactating women 4. patients who cannot tolerate preoperative biliary drainage or radical surgery 5. other situations that are not suitable for inclusion in clinical trials

Keywords: pancreatic head cancer obstructive jaundice preoperative biliary drainage prealbumin